Loss of spastin function results in disease-specific axonal defects in human pluripotent stem cell-based models of hereditary spastic paraplegia

Stem Cells

Volumn 32, Issue 2, 2014, Pages 414-423

  Denton, Kyle R ^a   Lei, Ling ^a   Grenier, Jeremy ^a   Rodionov, Vladimir ^b   Blackstone, Craig ^c   Li, Xue Jun ^a  

^a UNIVERSITY OF CONNECTICUT HEALTH CENTER   (United States)

^b Raymond and Beverly Sacker Laboratory of Genetics and Molecular Medicine   (United States)

^c NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE   (United States)

Author keywords

Axonal degeneration; Hereditary spastic paraplegia; Human embryonic stem cells; Induced pluripotent stem cells; RNA interference; Spastin

Indexed keywords

AXONAL DEGENERATION; HEREDITARY SPASTIC PARAPLEGIA; HUMAN EMBRYONIC STEM CELLS; INDUCED PLURIPOTENT STEM CELLS; RNA INTERFERENCE; SPASTIN;

ADENOSINE TRIPHOSPHATASES; ANIMALS; AXONS; DISEASE MODELS, ANIMAL; HUMANS; MITOCHONDRIA; NEURONS; PHENOTYPE; PLURIPOTENT STEM CELLS; SPASTIC PARAPLEGIA, HEREDITARY;

EID: 84894588547     PISSN: 10665099     EISSN: 15494918     Source Type: Journal    
DOI: 10.1002/stem.1569     Document Type: Article

References (63)

1. Fink JK, Hereditary spastic paraplegia. Neurol Clin 2002;20: 711-726.
2. Hazan J, Fonknechten N,Mavel D et al. Spastin, a new AAA protein, is altered in the most frequent form of autosomal dominant spastic paraplegia. Nat Genet 1999;23: 296-303.
3. Evans KJ, Gomes ER, Reisenweber SMet al. Linking axonal degeneration to microtubule remodeling by Spastin-mediated microtubule severing. J Cell Biol 2005;168: 599-606.
4. Roll-Mecak A, Vale RD. The Drosophila homologue of the hereditary spastic paraplegia protein, spastin, severs and disassembles microtubules. Curr Biol 2005;15: 650-655.
5. Salinas S, Carazo-Salas RE, Proukakis C et al. Human spastin has multiple microtubule-related functions. J Neurochem 2005;95: 1411-1420.
6. Lumb JH, Connell JW, Allison R et al. The AAA ATPase spastin links microtubule severing to membrane modelling. Biochim Biophys Acta 2012;1823: 192-197.
7. Solowska JM, Garbern JY, Baas PW. Evaluation of loss of function as an explanation for SPG4-based hereditary spastic paraplegia. Hum Mol Genet 2010;19: 2767-2779.
8. Pantakani DV, Swapna LS, Srinivasan N et al. Spastin oligomerizes into a hexamer and the mutant spastin (E442Q) redistribute the wild-type spastin into filamentous microtubule. J Neurochem 2008;106: 613-624.
9. Errico A, Ballabio A, Rugarli EI. Spastin, the protein mutated in autosomal dominant hereditary spastic paraplegia, is involved in microtubule dynamics. Hum Mol Genet 2002;11: 153-163.
10. Connell JW, Lindon C, Luzio JP et al. Spastin couples microtubule severing to membrane traffic in completion of cytokinesis and secretion. Traffic 2009;10: 42-56.
11. Yang D, Rismanchi N, Renvoise B et al. Structural basis for midbody targeting of spastin by the ESCRT-III protein CHMP1B. Nat Struct Mol Biol 2008;15: 1278-1286.
12. Yu W, Qiang L, Solowska JM et al. The microtubule-severing proteins spastin and katanin participate differently in the formation of axonal branches. Mol Biol Cell 2008; 19: 1485-1498.
13. Fassier C, Tarrade A, Peris L et al. Microtubule-targeting drugs rescue axonal swellings in cortical neurons from spastin knockout mice. Dis Model Mech 2013;6: 72-83.
14. Kasher PR, De Vos KJ, Wharton SB et al. Direct evidence for axonal transport defects in a novel mouse model of mutant spastininduced hereditary spastic paraplegia (HSP) and human HSP patients. J Neurochem 2009; 110: 34-44.
15. Solowska JM, Morfini G, Falnikar A et al. Quantitative and functional analyses of spastin in the nervous system: Implications for hereditary spastic paraplegia. J Neurosci 2008;28: 2147-2157.
16. Tarrade A, Fassier C, Courageot S et al. A mutation of spastin is responsible for swel-lings and impairment of transport in a region of axon characterized by changes in microtubule composition. Hum Mol Genet 2006;15: 3544-3558.
17. Takahashi K, Tanabe K, Ohnuki M et al. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell 2007;131: 861-872.
18. Yu J, Vodyanik MA, Smuga-Otto K et al. Induced pluripotent stem cell lines derived from human somatic cells. Science 2007;318: 1917-1920.
19. Ebert AD, Yu J, Rose FF, Jr. et al. Induced pluripotent stem cells from a spinal muscular atrophy patient. Nature 2009;457: 277-280.
20. Weimann JM, Zhang YA, Levin ME et al. Cortical neurons require Otx1 for the refinement of exuberant axonal projections to subcortical targets. Neuron 1999;24: 819-831.
21. Azim E, Shnider SJ, Cederquist GY et al. Lmo4 and Clim1 progressively delineate cortical projection neuron subtypes during development. Cereb Cortex 2009;19(suppl 1): i62-69.
22. Zhang N, An MC, Montoro D et al. Characterization of human Huntington's disease cell model from induced pluripotent stem cells. PLoS Curr 2010;2: RRN1193.
23. Somers A, Jean JC, Sommer CA et al. Generation of transgene-free lung disease-specific human induced pluripotent stem cells using a single excisable lentiviral stem cell cassette. Stem Cells 2010;28: 1728-1740.
24. Sommer CA, Sommer AG, Longmire TA et al. Excision of reprogramming transgenes improves the differentiation potential of iPS cells generated with a single excisable vector. Stem Cells 2010;28: 64-74.
25. Okita K, Matsumura Y, Sato Y et al. A more efficient method to generate integration-free human iPS cells. Nat Methods 2011;8: 409-412.
26. Wang ZB, Zhang X, Li XJ. Recapitulation of spinal motor neuron-specific disease phenotypes in a human cell model of spinal muscular atrophy. Cell Res 2013;23: 378-393.
27. Boisvert EM, Denton K, Lei L et al. The specification of telencephalic glutamatergic neurons from human pluripotent stem cells. J Vis Exp 2013, (74), e50321, doi: 10.3791/50321.
28. Li XJ, Zhang X, Johnson MA et al. Coordination of sonic hedgehog and Wnt signaling determines ventral and dorsal telencephalic neuron types from human embryonic stem cells. Development 2009; 136: 4055-4063.
29. Zeng H, Guo M, Martins-Taylor K et al. Specification of region-specific neurons including forebrain glutamatergic neurons from human induced pluripotent stem cells. PLoS One 2010;5: e11853.
30. Wang ZB, Zhang X, Li XJ. Recapitulation of spinal motor neuron-specific disease phenotypes in a human cell model of spinal muscular atrophy. Cell Res 2013;23: 378-393.
31. Schneider CA, Rasband WS, Eliceiri KW. NIH image to ImageJ: 25 years of image analysis. Nat Methods 2012;9: 671-675.
32. De Vos KJ, Chapman AL, Tennant ME et al. Familial amyotrophic lateral sclerosislinked SOD1 mutants perturb fast axonal transport to reduce axonal mitochondria content. Hum Mol Genet 2007;16: 2720-2728.
33. De Vos KJ, Sheetz MP. Visualization and quantification of mitochondrial dynamics in living animal cells. Methods Cell Biol 2007; 80: 627-682.
34. Sommer CA, Stadtfeld M, Murphy GJ et al. Induced pluripotent stem cell generation using a single lentiviral stem cell cassette. Stem Cells 2009;27: 543-549.
35. Abrahamsen G, Fan Y, Matigian N et al. A patient-derived stem cell model of hereditary spastic paraplegia with SPAST mutations. Dis Model Mech 2013;6: 489-502.
36. Orso G, Martinuzzi A, Rossetto MG et al. Disease-related phenotypes in a Drosophila model of hereditary spastic paraplegia are ameliorated by treatment with vinblastine. J Clin Invest 2005;115: 3026-3034.
37. An MC, Zhang N, Scott G et al. Genetic correction of Huntington's disease phenotypes in induced pluripotent stem cells. Cell Stem Cell 2012;11: 253-263.
38. Brennand KJ, Simone A, Jou J et al. Modelling schizophrenia using human induced pluripotent stem cells. Nature 2011; 473: 221-225.
39. Cooper O, Seo H, Andrabi S et al. Pharmacological rescue of mitochondrial deficits in iPSC-derived neural cells from patients with familial Parkinson's disease. Sci Transl Med 2012;4: 141ra190.
40. Dimos JT, Rodolfa KT, Niakan KK et al. Induced pluripotent stem cells generated from patients with ALS can be differentiated into motor neurons. Science 2008;321: 1218-1221.
41. Egawa N, Kitaoka S, Tsukita K et al. Drug screening for ALS using patient-specific induced pluripotent stem cells. Sci Transl Med 2012;4: 145ra104.
42. Lee G, Papapetrou EP, Kim H et al. Modelling pathogenesis and treatment of familial dysautonomia using patient-specific iPSCs. Nature 2009;461: 402-406.
43. Marchetto MC, Carromeu C, Acab A et al. A model for neural development and treatment of Rett syndrome using human induced pluripotent stem cells. Cell 2010; 143: 527-539.
44. Park IH, Arora N, Huo H et al. Diseasespecific induced pluripotent stem cells. Cell 2008;134: 877-886.
45. Soldner F, Hockemeyer D, Beard C et al. Parkinson's disease patient-derived induced pluripotent stem cells free of viral reprogramming factors. Cell 2009;136: 964-977.
46. Marchetto MC, Gage FH. Modeling brain disease in a dish: Really? Cell Stem Cell 2012;10: 642-645.
47. Arlotta P, Molyneaux BJ, Chen J et al. Neuronal subtype-specific genes that control corticospinal motor neuron development in vivo. Neuron 2005;45: 207-221.
48. Falnikar A, Baas PW. Critical roles for microtubules in axonal development and disease. Results Probl Cell Differ 2009;48: 47-64.
49. Fukushima N, Furuta D, Hidaka Y et al. Post-translational modifications of tubulin in the nervous system. J Neurochem 2009;109: 683-693.
50. Palazzo A, Ackerman B, Gundersen GG. Cell biology: Tubulin acetylation and cell motility. Nature 2003;421: 230.
51. Baas PW, Black MM. Individual microtubules in the axon consist of domains that differ in both composition and stability. J Cell Biol 1990;111: 495-509.
52. Dompierre JP, Godin JD, Charrin BC et al. Histone deacetylase 6 inhibition compensates for the transport deficit in Huntington's disease by increasing tubulin acetylation. J Neurosci 2007;27: 3571-3583.
53. Outeiro TF, Kontopoulos E, Altmann SM et al. Sirtuin 2 inhibitors rescue alphasynuclein-mediated toxicity in models of Parkinson's disease. Science 2007;317: 516-519.
54. Morfini GA, Burns M, Binder LI et al. Axonal transport defects in neurodegenerative diseases. J Neurosci 2009;29: 12776-12786.
55. Sharp DJ, Ross JL. Microtubule-severing enzymes at the cutting edge. J Cell Sci 2012; 125(Pt 11): 2561-2569.
56. Baas PW, Qiang L. Neuronal microtubules: When the MAP is the roadblock. Trends Cell Biol 2005;15: 183-187.
57. Millecamps S, Julien JP. Axonal transport deficits and neurodegenerative diseases. Nat Rev Neurosci 2013;14: 161-176.
58. Hafezparast M, Klocke R, Ruhrberg C et al. Mutations in dynein link motor neuron degeneration to defects in retrograde transport. Science 2003;300: 808-812.
59. Puls I, Jonnakuty C, LaMonte BH et al. Mutant dynactin in motor neuron disease. Nat Genet 2003;33: 455-456.
60. Zhao X, Alvarado D, Rainier S et al. Mutations in a newly identified GTPase gene cause autosomal dominant hereditary spastic paraplegia. Nat Genet 2001;29: 326-331.
61. Park SH, Zhu PP, Parker RL et al. Hereditary spastic paraplegia proteins REEP1, spastin, and atlastin-1 coordinate microtubule interactions with the tubular ER network. J Clin Invest 2010;120: 1097-1110.
62. Montenegro G, Rebelo AP, Connell J et al. Mutations in the ER-shaping protein reticulon 2 cause the axon-degenerative disorder hereditary spastic paraplegia type 12. J Clin Invest 2012;122: 538-544.
63. Kola I, Landis J. Can the pharmaceutical industry reduce attrition rates? Nat Rev Drug Discov 2004;3: 711-715.